{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T10:53:14Z","timestamp":1789210394179,"version":"build-2803163510"},"reference-count":124,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Until recently, vitamin K antagonists (VKAs) were the only available oral anticoagulants evaluated for long-term treatment of patients with coronary heart disease (CHD), particularly after an acute coronary syndrome (ACS). Despite efficacy in this setting, VKAs are rarely used because they are cumbersome to administer. Instead, the more readily manageable antiplatelet agents are the mainstay of prevention in ACS patients. This situation has the potential to change with the introduction of non-VKA oral anticoagulants (NOACs), which are easier to administer than VKAs because they can be given in fixed doses without routine coagulation monitoring. The NOACs include dabigatran, which inhibits thrombin, and apixaban, rivaroxaban and edoxaban, which inhibit factor Xa. Apixaban and rivaroxaban were evaluated in phase III trials for prevention of recurrent ischaemia in ACS patients, most of whom were also receiving dual antiplatelet therapy with aspirin and clopidogrel. Although at the doses tested rivaroxaban was effective and apixaban was not, both agents increased major bleeding. The role for the NOACs in ACS management, although promising, is therefore complicated, because it is uncertain how they compare with newer antiplatelet agents, such as prasugrel, ticagrelor or vorapaxar, and because their safety in combination with these other drugs is unknown. Ongoing studies are also now evaluating the use of NOACs in non-valvular atrial fibrillation patients, where their role is established, with coexistent ACS or coronary stenting. Focusing on CHD, we review the results of clinical trials with the NOACs and provide a perspective on their future incorporation into clinical practice.<\/jats:p><jats:p>Note: The review process for this paper was fully handled by Christian Weber, Editor in Chief.<\/jats:p>","DOI":"10.1160\/th15-09-0703","type":"journal-article","created":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T08:45:02Z","timestamp":1457426702000},"page":"685-711","source":"Crossref","is-referenced-by-count":24,"title":["Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis \u2013 Task Force on Anticoagulants in Heart Disease"],"prefix":"10.1160","volume":"115","author":[{"given":"Steen","family":"Husted","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicita","family":"Andreotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Arnesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedor","family":"Bachmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Baigent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Collet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Jespersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen Dalby","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Morais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Hvilsted","family":"Rasmussen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Ricci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Sibbing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agneta","family":"Siegbahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Storey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurrien ten","family":"Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek W. A.","family":"Verheugt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele De","family":"Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2017,11,28]]},"reference":[{"key":"10.1160\/TH15-09-0703-1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.02.008"},{"key":"10.1160\/TH15-09-0703-2","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-06-0443"},{"key":"10.1160\/TH15-09-0703-3","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-03-0228"},{"key":"10.1160\/TH15-09-0703-4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"10.1160\/TH15-09-0703-5","doi-asserted-by":"crossref","unstructured":"Renda G, et al. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Vs Warfarin in Phase III Atrial Fibrillation Trials. Am J Med 2015; 128: 1007-1014 e2","DOI":"10.1016\/j.amjmed.2015.03.034"},{"key":"10.1160\/TH15-09-0703-6","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-06-0403"},{"key":"10.1160\/TH15-09-0703-7","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-10-0772"},{"key":"10.1160\/TH15-09-0703-8","first-page":"1012","volume":"95","author":"Rona","year":"1966","journal-title":"Can Med Assoc J"},{"key":"10.1160\/TH15-09-0703-9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1969.tb16748.x"},{"key":"10.1160\/TH15-09-0703-10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198010163031601"},{"key":"10.1160\/TH15-09-0703-11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.955302"},{"key":"10.1160\/TH15-09-0703-12","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.1981.0101"},{"key":"10.1160\/TH15-09-0703-13","doi-asserted-by":"publisher","DOI":"10.1136\/heart.83.3.361"},{"key":"10.1160\/TH15-09-0703-14","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.71.4.699"},{"key":"10.1160\/TH15-09-0703-15","doi-asserted-by":"publisher","DOI":"10.5551\/jat.17608"},{"key":"10.1160\/TH15-09-0703-16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.071"},{"key":"10.1160\/TH15-09-0703-17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90111-X"},{"key":"10.1160\/TH15-09-0703-18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199005313222201"},{"key":"10.1160\/TH15-09-0703-19","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.1.61"},{"key":"10.1160\/TH15-09-0703-20","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.2685"},{"key":"10.1160\/TH15-09-0703-21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"10.1160\/TH15-09-0703-22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr373"},{"key":"10.1160\/TH15-09-0703-23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1618"},{"key":"10.1160\/TH15-09-0703-24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812033392303"},{"key":"10.1160\/TH15-09-0703-25","first-page":"989","volume":"2","author":"Stent","year":"1980","journal-title":"Lancet"},{"key":"10.1160\/TH15-09-0703-26","first-page":"871","volume":"2","author":"Gruppo","year":"1987","journal-title":"Lancet"},{"key":"10.1160\/TH15-09-0703-27","first-page":"349","volume":"2","author":"Randomised","year":"1988","journal-title":"Lancet"},{"key":"10.1160\/TH15-09-0703-28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(94)91161-4","volume":"343","author":"Fibrinolytic","year":"1994","journal-title":"Lancet"},{"key":"10.1160\/TH15-09-0703-29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"10.1160\/TH15-09-0703-30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200933"},{"key":"10.1160\/TH15-09-0703-31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.17.1892"},{"key":"10.1160\/TH15-09-0703-32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38985.646481.55"},{"key":"10.1160\/TH15-09-0703-33","doi-asserted-by":"publisher","DOI":"10.1253\/circj.68.308"},{"key":"10.1160\/TH15-09-0703-34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.09.077"},{"key":"10.1160\/TH15-09-0703-35","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu356"},{"key":"10.1160\/TH15-09-0703-36","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-2710"},{"key":"10.1160\/TH15-09-0703-37","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.203604"},{"key":"10.1160\/TH15-09-0703-38","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(10)70147-X"},{"key":"10.1160\/TH15-09-0703-39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11475-1"},{"key":"10.1160\/TH15-09-0703-40","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi714"},{"key":"10.1160\/TH15-09-0703-41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"10.1160\/TH15-09-0703-42","first-page":"V63","volume":"62","author":"Breddin","year":"1980","journal-title":"Circulation"},{"key":"10.1160\/TH15-09-0703-43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198209163071201"},{"key":"10.1160\/TH15-09-0703-44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7070.1429"},{"key":"10.1160\/TH15-09-0703-45","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02776-6"},{"key":"10.1160\/TH15-09-0703-46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199007193230302"},{"key":"10.1160\/TH15-09-0703-47","first-page":"499","volume":"343","author":"Anticoagulants","year":"1994","journal-title":"Lancet"},{"key":"10.1160\/TH15-09-0703-48","doi-asserted-by":"publisher","DOI":"10.1161\/hc0502.103329"},{"key":"10.1160\/TH15-09-0703-49","doi-asserted-by":"crossref","unstructured":"Herlitz J, et al. Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. Eur Heart J 2004; 25: 232-239","DOI":"10.1016\/j.ehj.2003.10.026"},{"key":"10.1160\/TH15-09-0703-50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09409-6"},{"key":"10.1160\/TH15-09-0703-51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020496"},{"key":"10.1160\/TH15-09-0703-52","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi485"},{"key":"10.1160\/TH15-09-0703-53","doi-asserted-by":"publisher","DOI":"10.1161\/hc1102.105594"},{"key":"10.1160\/TH15-09-0703-54","first-page":"II22","volume":"64","author":"Gohlke","year":"1981","journal-title":"Circulation"},{"key":"10.1160\/TH15-09-0703-55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-5223(19)37328-3","volume":"83","author":"McEnany","year":"1982","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1160\/TH15-09-0703-56","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.53.2.201"},{"key":"10.1160\/TH15-09-0703-57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90253-5"},{"key":"10.1160\/TH15-09-0703-58","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91815-4"},{"key":"10.1160\/TH15-09-0703-59","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.2.157"},{"key":"10.1160\/TH15-09-0703-60","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.4.386"},{"key":"10.1160\/TH15-09-0703-61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199604253341702"},{"key":"10.1160\/TH15-09-0703-62","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu278"},{"key":"10.1160\/TH15-09-0703-63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002358"},{"key":"10.1160\/TH15-09-0703-64","first-page":"1373","volume":"372","author":"Mauri","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1160\/TH15-09-0703-65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500857"},{"key":"10.1160\/TH15-09-0703-66","doi-asserted-by":"crossref","unstructured":"Udell JA, et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomised trials. Eur Heart J 2015; Epub ahead of print","DOI":"10.1093\/eurheartj\/ehv443"},{"key":"10.1160\/TH15-09-0703-67","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.271"},{"key":"10.1160\/TH15-09-0703-68","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.114967"},{"key":"10.1160\/TH15-09-0703-69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14287-0"},{"key":"10.1160\/TH15-09-0703-70","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr113"},{"key":"10.1160\/TH15-09-0703-71","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60738-8"},{"key":"10.1160\/TH15-09-0703-72","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.832139"},{"key":"10.1160\/TH15-09-0703-73","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr334"},{"key":"10.1160\/TH15-09-0703-74","unstructured":"Goldstein S. Safety evaluation of the factor Xa inhibitor TAK-442 in subjects with acute coronary syndromes: phase 2 AXIOM-ACS trial results. Available at: http:\/\/spo.escardio.org\/SessionDetails.aspx?eevtid=48&sessId=8199&subSessId =1307&searchQuery=&presId=59578&doc=Abstract#.UwnlCr9BpqM32"},{"key":"10.1160\/TH15-09-0703-75","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2011.02354.x"},{"key":"10.1160\/TH15-09-0703-76","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-07-0543"},{"key":"10.1160\/TH15-09-0703-77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105819"},{"key":"10.1160\/TH15-09-0703-78","doi-asserted-by":"crossref","unstructured":"Gibson CM, et al. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J 2011; 161: 815-821 e6","DOI":"10.1016\/j.ahj.2011.01.026"},{"key":"10.1160\/TH15-09-0703-79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"10.1160\/TH15-09-0703-80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"10.1160\/TH15-09-0703-81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.02.051"},{"key":"10.1160\/TH15-09-0703-82","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-03-0265"},{"key":"10.1160\/TH15-09-0703-83","unstructured":"Bayer Pharma AG. Xarelto\u00ae (rivaroxaban) Summary of Product Characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf. Accessed May 16, 2014"},{"key":"10.1160\/TH15-09-0703-84","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61273-1"},{"key":"10.1160\/TH15-09-0703-85","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.740324"},{"key":"10.1160\/TH15-09-0703-86","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008315310"},{"key":"10.1160\/TH15-09-0703-87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"10.1160\/TH15-09-0703-88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205512"},{"key":"10.1160\/TH15-09-0703-89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308075"},{"key":"10.1160\/TH15-09-0703-90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"10.1160\/TH15-09-0703-91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407024"},{"key":"10.1160\/TH15-09-0703-92","doi-asserted-by":"crossref","unstructured":"Bonaca MP, et al. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J 2014; 167: 437-444 e5","DOI":"10.1016\/j.ahj.2013.12.020"},{"key":"10.1160\/TH15-09-0703-93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.053"},{"key":"10.1160\/TH15-09-0703-94","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60263-X"},{"key":"10.1160\/TH15-09-0703-95","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62052-3"},{"key":"10.1160\/TH15-09-0703-96","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-01-0077"},{"key":"10.1160\/TH15-09-0703-97","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-11-0842"},{"key":"10.1160\/TH15-09-0703-98","doi-asserted-by":"crossref","unstructured":"Leonardi S, Becker RC. PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis. Handb Exp Pharmacol 2012: 239-260","DOI":"10.1007\/978-3-642-29423-5_10"},{"key":"10.1160\/TH15-09-0703-99","doi-asserted-by":"crossref","unstructured":"Tricoci P, et al. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. Am Heart J 2014; 168: 869-877 e1","DOI":"10.1016\/j.ahj.2014.09.002"},{"key":"10.1160\/TH15-09-0703-100","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61269-0"},{"key":"10.1160\/TH15-09-0703-101","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"10.1160\/TH15-09-0703-102","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs289"},{"key":"10.1160\/TH15-09-0703-103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.08.007"},{"key":"10.1160\/TH15-09-0703-104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.017"},{"key":"10.1160\/TH15-09-0703-105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.11.018"},{"key":"10.1160\/TH15-09-0703-106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060989"},{"key":"10.1160\/TH15-09-0703-107","first-page":"3238","volume":"36","author":"Andreotti","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1160\/TH15-09-0703-108","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-01-0061"},{"key":"10.1160\/TH15-09-0703-109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024964"},{"key":"10.1160\/TH15-09-0703-110","doi-asserted-by":"publisher","DOI":"10.1177\/2048872613517370"},{"key":"10.1160\/TH15-09-0703-111","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"10.1160\/TH15-09-0703-112","doi-asserted-by":"publisher","DOI":"10.1016\/j.crvasa.2014.03.001"},{"key":"10.1160\/TH15-09-0703-113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.02.050"},{"key":"10.1160\/TH15-09-0703-114","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-08-0580"},{"key":"10.1160\/TH15-09-0703-115","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu298"},{"key":"10.1160\/TH15-09-0703-116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.04.022"},{"key":"10.1160\/TH15-09-0703-117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503943"},{"key":"10.1160\/TH15-09-0703-118","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV10I9A174"},{"key":"10.1160\/TH15-09-0703-119","first-page":"467","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"10.1160\/TH15-09-0703-120","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.115386"},{"key":"10.1160\/TH15-09-0703-121","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht445"},{"key":"10.1160\/TH15-09-0703-122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"10.1160\/TH15-09-0703-123","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-08-0681"},{"key":"10.1160\/TH15-09-0703-124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.10.063"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH15-09-0703.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T20:50:07Z","timestamp":1600289407000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH15-09-0703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":124,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2017,11,20]]},"published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1160\/th15-09-0703","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}